Cannabinoid receptors and neurodegenerative diseases
作者： Riffat Tanveer , Niamh McGuinness , Stephanie Daniel , Aoife Gowran , Veronica A. Campbell
DOI: 10.1002/WMTS.64
关键词: Endocannabinoid system 、 Drug action 、 Neuroprotection 、 Endogenous cannabinoid 、 Neuroscience 、 Cannabinoid receptor 、 Disease 、 Medicine 、 Symptomatic relief 、 Amyotrophic lateral sclerosis
摘要: Neurodegenerative disorders carry a significant social and economic burden, the effective treatment of such illnesses remains challenge for neuroscientists neurologists. Although advances have been made on our understanding molecular mechanisms underlying neurodegenerative diseases, translation this knowledge into therapeutic treatments has limited. There is still dearth curative most disorders, with symptomatic relief being principal target drug action. Endocannabinoids belong to an evolutionary conserved neuro-signaling system certain endogenous exogenous components are emerging as clinically promising neuroprotective agents due their anti-oxidative, anti-excitotoxic, anti-inflammatory properties. The cannabinoid is, therefore, potential several conditions, Alzheimer's disease, Parkinson's Huntington's amyotrophic lateral sclerosis. Research drugs that modulate tone intense. Recent evidence implicates endocannabinoid pharmacological circumvent disease pathology. WIREs Membr Transp Signal 2012, 1:633–639. doi: 10.1002/wmts.64 For further resources related article, please visit website.
elsevier.com
sci-hub.se 参考文章(45)
Varda Nadler, Raphael Mechoulam, Mordechai Sokolovsky, The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates receptor-mediated neurotoxicity in primary cultures of rat forebrain Neuroscience Letters. ,vol. 162, pp. 43- 45 ,(1993) , 10.1016/0304-3940(93)90555-Y
Javier Fernández-Ruiz, Miguel Moreno-Martet, Carmen Rodríguez-Cueto, Cristina Palomo-Garo, María Gómez-Cañas, Sara Valdeolivas, Carmen Guaza, Julián Romero, Manuel Guzmán, Raphael Mechoulam, José A Ramos, Prospects for cannabinoid therapies in basal ganglia disorders British Journal of Pharmacology. ,vol. 163, pp. 1365- 1378 ,(2011) , 10.1111/J.1476-5381.2011.01365.X
Aoife Gowran, Joanne McKiernan, Veronica A. Campbell, Janis Noonan, Riffat Tanveer, Allan Klompas, Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons. Journal of Biological Chemistry. ,vol. 285, pp. 38543- 38554 ,(2010) , 10.1074/JBC.M110.162040
EL Scotter, CE Goodfellow, ES Graham, M Dragunow, M Glass, Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. British Journal of Pharmacology. ,vol. 160, pp. 747- 761 ,(2010) , 10.1111/J.1476-5381.2010.00773.X
G Esposito, C Scuderi, C Savani, L Steardo, D De Filippis, P Cottone, T Iuvone, V Cuomo, L Steardo, Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression British Journal of Pharmacology. ,vol. 151, pp. 1272- 1279 ,(2007) , 10.1038/SJ.BJP.0707337
Cristina Benito, Estefanía Núñez, Rosa M. Tolón, Erica J. Carrier, Alberto Rábano, Cecilia J. Hillard, Julián Romero, Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains The Journal of Neuroscience. ,vol. 23, pp. 11136- 11141 ,(2003) , 10.1523/JNEUROSCI.23-35-11136.2003
Malú G. Tansey, Matthew S. Goldberg, Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease. ,vol. 37, pp. 510- 518 ,(2010) , 10.1016/J.NBD.2009.11.004
Masoud Haghani, Mahyar Janahmadi, Mohammad Shabani, Protective effect of cannabinoid CB1 receptor activation against altered intrinsic repetitive firing properties induced by Aβ neurotoxicity Neuroscience Letters. ,vol. 507, pp. 33- 37 ,(2012) , 10.1016/J.NEULET.2011.11.044
Koen Van Laere, Cindy Casteels, Sophie Lunskens, Karolien Goffin, Igor D. Grachev, Guy Bormans, Wim Vandenberghe, Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo Neurobiology of Aging. ,vol. 33, pp. 620- ,(2012) , 10.1016/J.NEUROBIOLAGING.2011.02.009
Michael J. Passmore, The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International Journal of Geriatric Psychiatry. ,vol. 23, pp. 116- 117 ,(2008) , 10.1002/GPS.1828